ArticleAnnals of medicine and surgery (2012)2026
Tumor-derived exosomes as predictors of chemotherapy resistance in gastric cancer.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy resistance is a major obstacle in gastric cancer, limiting the efficacy of systemic therapy and contributing to poor survival. Tumor-derived exosomes are key mediators of chemoresistance, carrying microRNAs, long noncoding RNAs, and proteins that modulate apoptosis, drug efflux, and tumor-microenvironment interactions. Evidence from high-incidence countries, such as China and Japan, associates specific exosomal signatures with poor treatment response, and translational studies in Europe and North America are exploring their prognostic and predictive utility. Despite technical advances, clinical translation is hampered by inconsistent protocols, small cohorts, and limited regulatory frameworks. This letter reviews the biological and clinical evidence for exosome-mediated chemoresistance in gastric cancer and advocates for standardized methodologies, global validation studies, and integration into precision oncology pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.